Symbiotec Pharmalab IPO Review: GMP, Details, Size, Retail Quota & More
The Symbiotec Pharmalab IPO is set to open for subscription on August 24, 2026, with a price band of ₹938 to ₹988 per share. The IPO comprises a fresh issue of up to ₹150 crore and an Offer for Sale (OFS) of up to ₹1,607 crore, taking the total issue size to approximately ₹1,757 crore.
Symbiotec Pharmalab is a research-driven API manufacturer with a strong position in corticosteroid and steroidal-hormone APIs. The company reported revenue from operations of ₹869.14 crore in FY26, while its net profit stood at ₹109.90 crore. At the upper price band, the IPO commands a P/E multiple of approximately 55.44x to 56.8x.
The valuation is high on an absolute basis but remains lower than several listed peers. The company also has global market leadership in selected API segments, vertically integrated manufacturing capabilities and plans to expand into complex injectables and biotechnology products. At the same time, high revenue concentration, significant OFS, regulatory and tax matters, and liquidity constraints are important risks for investors to consider.
Symbiotec Pharmalab IPO Details
Here is a snapshot of the key Symbiotec Pharmalab IPO details:
What is the Symbiotec Pharmalab IPO Size?
The total Symbiotec Pharmalab IPO size is up to ₹1,757 crore. Of this, up to ₹150 crore will come through a fresh issue, while up to ₹1,607 crore will be offered by existing shareholders through an Offer for Sale.
The OFS includes shares offered by promoter selling shareholder Satwani Holdings LLP and investor selling shareholders Rosewood Investments and India Business Excellence Fund – III. The proposed OFS comprises:
The company will not receive any proceeds from the OFS. This is an important consideration for investors because approximately 91.5% of the total IPO size represents secondary sales, while only around 8.5% represents fresh capital being raised by the company.
How will Symbiotec Use the Fresh Issue Proceeds?
Symbiotec plans to use the net proceeds from the ₹150 crore fresh issue primarily for debt repayment. Approximately ₹112.5 crore will be used for the prepayment and/or repayment, either fully or partly, of certain outstanding borrowings. The remaining proceeds will be used for general corporate purposes. The debt repayment could help reduce debt servicing costs and improve the company's debt-equity position.
Symbiotec Pharmalab IPO Financial Performance
Symbiotec has recorded consistent growth in revenue from operations over the last three fiscal years. Revenue increased from ₹716.25 crore in FY24 to ₹869.15 crore in FY26, representing a 10.16% CAGR. Its net profit increased to ₹109.90 crore in FY26.
*Adjusted ROCE excludes the non-commercialised greenfield units Knovea and Symbiotec Zenfold.
The company's diluted weighted average EPS for the last three fiscal years is ₹18.29, while basic and diluted EPS for FY26 were ₹19.10 and ₹19.00, respectively.
Symbiotec Pharmalab IPO Valuation
At the upper price band of ₹988, Symbiotec's pre-IPO P/E multiple is approximately 55.44x to 56.8x. This valuation is high when viewed on an absolute basis. However, it is lower than the P/E multiples of several listed companies in the comparison set.
The comparison suggests that Symbiotec is being offered at a lower P/E multiple than the listed peers mentioned above. However, its 9.48% RoNW and 11.19% ROE provide limited comfort at the proposed valuation.
What are the Key Strengths of Symbiotec Pharmalab?
Global Leadership in Niche APIs
Symbiotec holds significant global market shares in its key API segments. In FY26, the company accounted for 38.2% of global volume market share in corticosteroids and 23.8% in steroidal-hormone APIs. This provides the company with a strong position in specialised pharmaceutical markets.
High Entry Barriers
The company's operations involve complex multi-step chemical synthesis, sophisticated fermentation processes and stringent regulatory requirements. These factors can make it difficult for generic competitors to establish comparable capabilities at scale.
Large-Scale Fermentation Capacity
Symbiotec operates 700 KL of industrial-scale fermentation capacity. Its backward integration also helps reduce dependence on imported raw intermediates, including those sourced from China.
Expansion Into Complex Injectables
The company has developed Double-Chamber Vials (DCVs) in-house, including Methylprednisolone and Hydrocortisone sodium succinate injections. These products target a US market estimated at USD 288 million, with launches expected in FY27.
Long-Term Customer Relationships
Symbiotec has established long-term relationships with its customers. The average relationship tenure of its top five and top ten customers exceeds 10 years. Customers with relationships exceeding seven years contributed 69.49% of operating revenue in FY26.
What are the Key Risks of the Symbiotec Pharmalab IPO?
High Revenue Concentration
Symbiotec remains heavily dependent on API sales. Around 96.07% of FY26 revenue came from the sale of APIs. The concentration is also visible at the product level, with the company's top five APIs contributing 62.27% of operating revenue.
Large OFS Component
The IPO is heavily weighted towards the OFS component. Of the total ₹1,757 crore issue, ₹1,607 crore will go to existing selling shareholders, while only ₹150 crore will be raised by the company through the fresh issue.
Audit Qualification
The statutory auditors disclosed a qualification concerning a leasehold land parcel with a carrying value of ₹37.52 crore in FY26, for which registration of the title deed remains pending.
Tax Litigation
The company has ₹150.79 crore in outstanding direct tax litigation. It also received reassessment notices in March 2026 concerning the application of Section 115BAA and alleged tax short-levies and interest. The disputes across the specified assessment years total ₹50.79 crore.
Liquidity Pressure
Symbiotec's current ratio declined from 1.45 in FY24 to 1.04 in FY25 and then to 0.92 in FY26. Current liabilities increased to ₹527.57 crore, while current borrowings rose to ₹319.50 crore. Cash and cash equivalents stood at only ₹10.04 crore at the end of FY26. This indicates pressure on the company's short-term liquidity position.
What is Symbiotec's Biotechnology and Injectables Strategy?
Symbiotec is also expanding beyond its established API business. The company's 700 KL fermentation capacity is being leveraged for biotechnology initiatives, including development pipelines for GLP-1 and insulin.
It is also pursuing commercialisation of its Double-Chamber Vial products. The company is in discussions with multiple global speciality pharmaceutical companies regarding licensing these products. These initiatives could provide additional growth opportunities if successfully commercialised.
How has Symbiotec Expanded Its Manufacturing Capacity?
Symbiotec's balance sheet shows a significant increase in capitalised assets during FY26. Capital work-in-progress fell from ₹568.17 crore in FY25 to ₹64.48 crore as of March 31, 2026. During FY26, the company capitalised ₹722.10 crore from CWIP into operational property, plant and equipment.
As a result, the net book value of PPE increased to ₹1,084.39 crore in FY26 from ₹401.54 crore in FY25. The company also spent ₹4.09 crore on upgrading its in-house R&D facilities during FY26.
The transition indicates that significant capital expenditure projects have moved from the development stage into operational assets.
What is Symbiotec's Customer and Geographic Mix?
Symbiotec has a strong base of long-standing customers while also expanding in regulated international markets. Customers with relationships of more than seven years accounted for 69.49% of operating revenue in FY26.
The company added 101 new distinct customers in FY26, compared with 96 in FY25 and 89 in FY24. The US market also recorded significant growth. Revenue from the US increased from ₹30.20 crore in FY25 to ₹114 crore in FY26, representing growth of more than 277%.
Europe remained an important market, contributing 29.11% of operating revenue. However, customer concentration remains a factor to watch, with the top three customers accounting for 25% of total revenue in FY26.
Symbiotec Pharmalab IPO: What are the Key Pre-IPO Transactions?
The IPO has been preceded by several notable capital structure and shareholder transactions. On August 17, 2026, promoters and Satwani Holdings LLP transferred a combined 505,000 shares to Motilal Oswal India Excellence Fund – Mid to Mega Series III at ₹988 per share, matching the upper end of the IPO price band.
The weighted average cost of acquisition for Rosewood Investments and India Business Excellence Fund – III was ₹147.21 per share, while Satwani Holdings LLP had a weighted average acquisition cost of ₹49.43 per share.
The company also completed a 6:5 rights issue at ₹276 per share in December 2025, raising ₹193.19 crore. Earlier, on May 29, 2025, the company completed a 1:5 stock split, reducing the face value from ₹10 to ₹2.
Symbiotec Pharmalab IPO: Key Compliance and Governance Concerns
Investors should also consider several disclosures in the company's regulatory filings.
The statutory auditors highlighted that although the company uses SAP accounting software, the mandatory audit trail or edit-log feature was not enabled for changes made through administrative or privileged access rights for substantial periods, including from April 1, 2025, to March 26, 2026.
There are also promoter share pledges involving 82,98,243 shares, representing 13.22% of pre-offer capital. These shares are pledged in favour of Beacon Trusteeship Limited to secure a ₹197 crore debenture facility issued by Satwani Holdings India Private Limited.
The debenture holder, Nomura Capital (India) Private Limited, is a direct affiliate of Nomura Financial Advisory, one of the Book Running Lead Managers for the IPO.
Additionally, Motilal Oswal Investment Advisors, another Book Running Lead Manager, is an associate of India Business Excellence Fund – III, an investor selling shareholder. As a result, Motilal Oswal is legally restricted and involved only in the marketing of the Offer.
Symbiotec Pharmalab IPO Rating: What are Experts Saying
The Swastika Expert Team has given the Symbiotec Pharmalab IPO a “SUBSCRIBE” rating. The rationale includes Symbiotec's strategic position in specialised APIs, global leadership in corticosteroid and steroidal-hormone APIs, high entry barriers and vertically integrated manufacturing capabilities.
At ₹988 per share, the valuation of approximately 56.8x P/E is considered high in absolute terms but remains below the multiples of several listed peers. At the same time, the expert assessment highlights the company's FY26 ROE of approximately 11.19% and ROCE of approximately 11.56% as offering limited short-term valuation comfort.
The substantial OFS component is another factor to consider, with ₹1,607 crore going to existing shareholders compared with ₹150 crore raised as fresh capital. Overall, the expert team considers the IPO suitable for long-term investors seeking specialised exposure to a high-barrier, vertically integrated API and biotechnology business.
Symbiotec Pharmalab IPO Review: Should You Apply?
The Symbiotec Pharmalab IPO review presents a mixed picture for investors.
On the positive side, the company has established a strong position in specialised API markets, significant global market shares in corticosteroids and steroidal-hormone APIs, large-scale fermentation capabilities and long-standing customer relationships. Its expansion into complex injectables, GLP-1 and insulin also provides additional areas of potential growth.
The company's revenue has grown at a 10.16% CAGR between FY24 and FY26, while FY26 EBITDA margin stood at 26.59%. However, investors also need to consider the risks. The business is highly dependent on APIs, with 96.07% of FY26 revenue coming from API sales. The IPO itself is dominated by an OFS, with only ₹150 crore of the ₹1,757 crore issue representing fresh capital for the company.
The company's 0.92 current ratio, tax disputes, audit qualification and regulatory matters add further considerations. At the upper price band of ₹988, the IPO is valued at approximately 55.44x–56.8x earnings. While this is lower than the P/E multiples of several listed peers, the company's ROE and RoNW remain relatively moderate.
Swastika Investmart's View
The Swastika Expert Team has rated the IPO “SUBSCRIBE” and considers it suitable for long-term investors seeking exposure to a specialised, research-driven API and biotechnology player. Investors should, however, assess the IPO based on their own investment horizon and risk appetite rather than relying solely on the rating or peer valuation comparison.
Symbiotec Pharmalab IPO Allotment and Listing Timeline
The Symbiotec Pharmalab IPO is scheduled to open on August 24, 2026 and close on August 27, 2026.
Symbiotec Pharmalab IPO FAQs
What is the Symbiotec Pharmalab IPO price band?
The Symbiotec Pharmalab IPO price band is ₹938 to ₹988 per share.
What is the Symbiotec Pharmalab IPO size?
The total IPO size is up to ₹1,757 crore, comprising a fresh issue of up to ₹150 crore and an OFS of up to ₹1,607 crore.
What is the Symbiotec Pharmalab IPO retail quota?
The information provided does not specify the percentage reserved for retail investors. The minimum retail application is 15 shares, requiring an investment of ₹14,820 at the upper price band.
What is the Symbiotec Pharmalab IPO GMP today?
The information provided does not include the latest GMP figure. The grey market premium should be checked against the latest available market data before making any assessment of the potential listing price.
When does the Symbiotec Pharmalab IPO open?
The IPO opens on August 24, 2026 and closes on August 27, 2026.
What is the Symbiotec Pharmalab IPO listing date?
The Symbiotec Pharmalab IPO is scheduled to list on September 1, 2026, on NSE and BSE.
What is the Swastika rating for the Symbiotec Pharmalab IPO?
The Swastika Expert Team has given the Symbiotec Pharmalab IPO a “SUBSCRIBE” rating, with the IPO considered suitable for long-term investors seeking specialised exposure to the API and biotechnology space.
Conclusion
The Symbiotec Pharmalab IPO combines a specialised API business, global market positions and vertically integrated manufacturing with a valuation that is lower than several listed peers but still high in absolute terms. The company has demonstrated revenue growth and maintains strong positions in corticosteroid and steroidal-hormone APIs. Its fermentation capacity and pipeline in complex injectables, GLP-1 and insulin could provide additional growth opportunities.
The Swastika Expert Team has assigned a “SUBSCRIBE” rating, particularly for long-term investors seeking specialised exposure to the API and biotechnology segment. However, investors should consider the IPO's valuation, risks and their own investment objectives before making a decision. For more IPO and stock market-related updates, visit Swastika Investmart and stay updated with the latest market developments.
